Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor-Reference-Cited by-同舟云学术

Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor

Published:2020-11-09 Issue:7 Volume:25 Page:1828-1836
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:J Gastrointest Surg

Author:

Cavnar Michael J.^ORCID,Seier Kenneth,Gönen Mithat,Curtin Christina,Balachandran Vinod P.,Tap William D.,Antonescu Cristina R.,Singer Sam,DeMatteo Ronald P.

Funder

National Institutes of Health

The David Foundation

Betsy Levine-Brown and Marc Brown

GIST Cancer Research Fund

David and Monica Gorin

Kristin Ann Carr Fellowship

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s11605-020-04843-9.pdf

Reference30 articles.

1. Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(15):1563-70.

2. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Annals of surgical oncology. 2007;14(1):14-24.

3. Rubio J, Marcos-Gragera R, Ortiz MR, Miro J, Vilardell L, Girones J, Hernandez-Yague X, Codina-Cazador A, Bernado L, Izquierdo A, Colomer R. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. European journal of cancer. 2007;43(1):144-8.

4. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Annals of surgery. 2007;245(3):347-52.

5. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. Journal of surgical oncology. 2009;99(1):42-7.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors;World Journal of Surgery;2024-05-17

2. Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach;Gastric Cancer;2023-06-23

3. Retrospective study of the clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients;Annals of Diagnostic Pathology;2022-12

4. Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study;Frontiers in Pharmacology;2022-09-27

5. Gastrointestinal Stromal Tumor;Surgical Oncology Clinics of North America;2022-07